Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

Ken Kato; Byoung Chul Cho; Masanobu Takahashi; Morihito Okada; Chen-Yuan Lin; Keisho Chìn; Shigenori Kadowaki; Myung‐Ju Ahn; Yasuo Hamamoto; Yuichiro� Doki; Chueh‐Chuan Yen; Yutaro Kubota; Sung‐Bae Kim; Chih‐Hung Hsu; Eva Holtved; Ioannis Xynos; Mamoru Kodani; Yuko Kitagawa

doi:10.1016/s1470-2045(19)30626-6

Keywords

Refractory (planetary science)NivolumabChemotherapyMedicineInternal medicineOncologyOpen labelEsophageal squamous cell carcinomaBasal cellClinical trialCarcinomaImmunotherapyCancerBiology

Affiliated Institutions

Related Publications

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

Takashi Kojima , Manish A. Shah , Kei Muro +24 more

PURPOSE Patients with advanced esophageal cancer have a poor prognosis and limited treatment options after first-line chemotherapy. PATIENTS AND METHODS In this open-label, phas...

2020 Journal of Clinical Oncology 1110 citations

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Y. Janjigian , Kohei Shitara , Markus Moehler +26 more

First-line chemotherapy for advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma has a median ov...

2021 The Lancet 2580 citations

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen , Denis Soulières , Christophe Le Tourneau +97 more

There are few effective treatment options for patients with recurrent or metastatic head-and-neck squamous cell carcinoma. Pembrolizumab showed antitumour activity and manageabl...

2018 The Lancet 1593 citations

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Howard West , Michael McCleod , Maen Hussein +17 more

Atezolizumab (a monoclonal antibody against PD-L1), which restores anticancer immunity, improved overall survival in patients with previously treated non-small-cell lung cancer ...

2019 The Lancet Oncology 1597 citations

Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies.

Mario Sznol , John D. Powderly , David C. Smith +7 more

2506 Background: Programmed death-1 (PD-1), a T-cell inhibitory receptor, may suppress antitumor immunity. MDX-1106, a fully human IgG4 PD-1 blocking antibody, has shown antitum...

2010 Journal of Clinical Oncology 84 citations

Publication Info

Year: 2019
Type: article
Volume: 20
Issue: 11
Pages: 1506-1517
Citations: 1165
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1165

OpenAlex

Cite This

APA Style

                            
                                
                                    Ken Kato, 
                                
                                    Byoung Chul Cho, 
                                
                                    Masanobu Takahashi
                                
                                et al.
                            
                            (2019). 
                            Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. 
                            The Lancet Oncology
                            , 20
                            (11)
                            , 1506-1517.
                            https://doi.org/10.1016/s1470-2045(19)30626-6
                        

Identifiers

DOI: 10.1016/s1470-2045(19)30626-6